Tag: Prescription Drugs
CVD Risk Up With β2-Agonist, Antimuscarinic Antagonist Start
New use of long-acting β2-agonists, antimuscarinic antagonists tied to higher CVD risk in first 30 days
Predictors of Infliximab Response in Ulcerative Colitis Identified
Baseline Mayo Endoscopic Score, CRP/albumin ratio predict treatment response and risk for colectomy
Few Immuno-Oncology Agents Reach ASCO Efficacy Thresholds
Durable survival, response rates rarely recognized as significant by current oncology value frameworks
Pharmaceutical Aids Not Found to Be Helpful for Smoking Cessation
No evidence that varenicline, bupropion, or nicotine replacement increase probability of abstinence
Increase Seen in Gabapentinoid Use From 2002 to 2015
More than three-fold increase in percentage of adults using gabapentin and/or pregabalin
Out-of-Pocket Costs Correlate With Receipt of Cancer Care
Across cancers, higher costs tied to higher rates of oral prescription abandonment, delayed initiation
More Than a Third of Patients Do Not Respond to Antiepileptics
Overall, 89.9 percent of patients who achieve seizure control do so with first, second AED regimen
Rituximab Effective for Lupus-Associated Cytopenia
Overall initial response rate of 86 percent in 71 patients, with complete response for 60.5 percent
Plasma Volume Changes May Mediate Effects of Empagliflozin
Findings suggest reduced CV mortality risk mediated by effects on markers of plasma volume
FDA Removes Boxed Warning From Certain Asthma Medications
Decision applies to long-acting beta agonists used in combination with inhaled corticosteroids
